News & Press

latest press coverage

BridgeBio Pharma and Maze Therapeutics Establish Joint Venture to Advance Precision Medicine to Treat Cardiovascular Disease

December 7, 2020

Maze Therapeutics and Alloy Therapeutics Form Broadwing Bio to Develop Antibody Therapies for Genetically Validated Targets in Ophthalmic Diseases

Maze Therapeutics Expands Experienced Management Team with Appointment of Sarah Noonberg, M.D., Ph.D., as Chief Medical Officer

October 6, 2020

latest media coverage

Forbes: Third Rock And ARCH-Backed Genetics Startup Launches With Nearly $200 Million

February 28, 2019

Forbes — A startup aimed at identifying genetic modifiers (genes that impact how other ones are expressed) to develop new drugs launched Thursday with $191 million in funding from investors Third Rock Ventures and ARCH Venture Partners, among others. Maze…

View full article

Xconomy: With $191M Haul, Maze Therapeutics Takes Aim at Genetic Diseases

Xconomy San Francisco — People who share the same disease-causing genetic mutation can have a wide range of severity in their disease. Some don’t get sick at all. Environment can play a role, but with ever-more genetic data available, scientists…

View full article

MIT Technology Review: The secret to a new drug could be hiding in your genes

MIT Technology Review — Sickle-cell disease is caused by a one-letter spelling mistake in the hemoglobin gene. But not everyone who inherits the error suffers the worst effects of the blood disease. By 2008, scientists had figured out why. It’s…

View full article

latest press coverage

latest media coverage

want to get a hold of a representative?

Media Inquires